<DOC>
	<DOCNO>NCT01610388</DOCNO>
	<brief_summary>This first time human ( FTIH ) study first administration GSK1322322 intravenous formulation investigate safety , tolerability , pharmacokinetics healthy subject . One cohort subject undergo bronchoalveolar lavage ( BAL ) determination GSK1322322 concentration lung simultaneous comparison plasma concentration evaluate drug penetration lung . The study evaluate absolute bioavailability oral tablet formulation compare IV formulation.In addition , Amendment 01 enable investigation improve IV formulation ( GSK1322322J mesylate salt ) additional repeat dose cohort supra-therapeutic cohort .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics Oral Intravenous GSK1322322 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include [ medical history , physical examination , laboratory test ECGs . A subject clinical abnormality laboratory parameter outside reference range population study may include discretion Investigator find unlikely introduce additional risk factor interfere study procedure . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication final follow visit . Body weight great equal 50 kilogram body mass index ( BMI ) 18.529.9 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB le 450 millisecond ( msec ) ; QTcB le 480 msec subject Bundle Branch Block Screening ECG A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Contraindications bronchoalveolar lavage include hypercapnia great 50 mm Hg , refractory hypoxemia , reactive airway disease asthma , unstable angina acute myocardial infarction last 6 month , heart failure , severe hemostatic alteration ( Cohort C ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , within 5 day follow discontinuation GSK1322322 ( sensitive narrow therapeutic index CYP3A4 substrates ) , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Use antacid , H2 blocker , proton pump inhibitor , vitamin , iron supplement within 7 day prior first dose study medication duration trial , include followup . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History sensitivity medication use study , ie Atropine , Midazolam , Fentanyl , Lidocaine , Codeine ( Cohort C ) , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 milliliter within 56 day period . Pregnant female determine positive [ serum urine ] test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice [ and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice ] 7 day prior first dose study medication . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) : Heart rate : male less 45 great 100 beat per minute ( bpm ) females less 50 great 100bpm . PR interval le 120 great 220msec , QRS duration le 70 great 120 msec , QTcB great 450msec . Evidence previous myocardial infarction ( include ST segment change associate repolarization ) . Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , Wolf Parkinson White [ WPW ] syndrome ) , sinus pause &gt; 3 second , nonsustained sustain ventricular tachycardia ( great equal 3 consecutive ventricular ectopic beat ) significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>healthy subject</keyword>
	<keyword>double-blind</keyword>
	<keyword>FTIH</keyword>
	<keyword>dose-escalation</keyword>
	<keyword>absolute bioavailability</keyword>
	<keyword>GSK1322322</keyword>
	<keyword>BAL</keyword>
</DOC>